ED: Getting the rollout back on track

When the pandemic began to devastate India at the beginning of this year, with death rates breaking records every day, it was not surprising that our neighbouring nation decided to focus on saving its own citizens at all cost.

This meant, unfortunately, that the deal Bangladesh had entered into with the Serum Institute of India to purchase 30 million doses of the AstraZeneca vaccine -- with a rollout plan of five million doses each month -- had to be put on hold after around 10 million doses, of which 3.3 million were a generous gift from our Indian neighbours.

There is no denying that India did what had to be done, but it has also meant that Bangladesh’s initial plan to vaccinate a significant portion of the population went out window, continuing to leave us vulnerable to Covid-19.

As such, we hope that reports indicating India’s decision to release the vaccines which have already been paid for by Bangladesh are true, as Bangladesh hits a new highest daily infection rate in two months and ponders a strict two-week nationwide lockdown.

India’s willingness to hold up its end of the bargain would be much appreciated, even more so if done quickly, with current projections indicating delivery at the end of July or slightly later, dependent on the situation we find ourselves in by then.

This situation should also act as a lesson to our government officials on the importance of diversifying our sources, not only with regards to acquiring vaccines, but in most areas of governance, whereby dependence on one ministry, industry, or nation does not bode well for sustainable development and leaves us vulnerable to unpredictable events.